Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
One Percent Rule Checklist For Safer Forex Trading Risk 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
BOSTON, April 18, 2017 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to discuss its first quarter 2017 financial results and provide corporate updates.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 8810002. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617.466.3511 [email protected]
